Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-27T20:14:50.022Z Has data issue: false hasContentIssue false

The impact of dose on the real-world effectiveness of vortioxetine in outpatients with mdd in greece

Published online by Cambridge University Press:  13 August 2021

E. Papalexi*
Affiliation:
Medical, Lundbeck Hellas, Athens, Greece
P. Kakkavas
Affiliation:
Psychiatric, Private Office, Athens, Greece
D. Vassos
Affiliation:
Psychiatric, Private Office, Athens, Greece
T. Mylonaki
Affiliation:
Psychiatric, Private Office, Athens, Greece
D. Partsafyllidis
Affiliation:
Psychiatric, Private Office, Thesalonik, Greece
S. Mageiria
Affiliation:
Psychiatric, Private Office, Thesaloniki, Greece
C. Nestoris
Affiliation:
Psychiatric, Private Office, Thesaloniki, Greece
A. Galanopoulos
Affiliation:
Medical, Lundbeck Hellas, Athens, Greece
A. Ettrup
Affiliation:
Medical, H Lundbeck A/S, Valby, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The current treatment goal in Major Depressive Disorder (MDD) is functional recovery (Zimmerman M et al, 2012). However, finding the “right dose for the right patient” may be challenging and the dose-response relationship for antidepressant efficacy remains controversial (Hieronymus F et al, 2016). Efficacy evaluated by MADRS increases with higher vortioxetine doses, based on meta-analysis data (Thase ME et al, 2016).

Objectives

The aim of this exploratory analysis was to assess the impact of different doses on vortioxetine effectiveness in clinical practice in Greece.

Methods

In this non-interventional study, open-label vortioxetine was administered at a flexible dosage (5-20 mg/d). Patients receiving 5/10 mg vortioxetine (group A), at the end of the study, were compared to patients receiving 15/20mg vortioxetine (group B). At baseline, 1 and 3 months, depressive symptoms and functioning were assessed by MADRS and SDS. Multiple regression was used for the statistical analyses.

Results

The study included 336 MDD patients. At the end of the study, 64.3% (n=200) of patients were receiving 15/20 mg vortioxetine. Higher vortioxetine dose at month 3 was significantly correlated with higher MADRS total score at baseline (p<0.001). SDS total score change from baseline to month 3 was significantly associated with vortioxetine dose (p<0.001), with group A and group B showing improvements of -9.2±8.2 and -12.1±6.0, respectively- whereas such association was not observed for MADRS total score.

Conclusions

In conclusion, patients with more severe depressive symptoms were treated with higher antidepressant doses. However, beyond symptom improvement, vortioxetine effectiveness on patient functioning seems to increase with higher doses.

Conflict of interest

A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas. A. Ettrup is a full-time employee in H. Lundbeck A/S.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.